Research programme: vitronectin receptor antagonists - Uriach

Drug Profile

Research programme: vitronectin receptor antagonists - Uriach

Alternative Names: Vitronectin receptor antagonists research programme - Uriach

Latest Information Update: 20 Jan 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Uriach
  • Class
  • Mechanism of Action Integrin alphaVbeta3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer; Coronary artery restenosis; Osteoporosis; Vascular restenosis

Most Recent Events

  • 20 Jan 2004 Discontinued - Preclinical for Cancer in Spain (unspecified route)
  • 20 Jan 2004 Discontinued - Preclinical for Coronary artery restenosis in Spain (unspecified route)
  • 20 Jan 2004 Discontinued - Preclinical for Osteoporosis in Spain (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top